# US 2016/0250245 A1 · Methods and Pharmaceutical Composition for the Treatment of Polyomavirus Infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250245 A1
- Document ID: US20160250245A1
- Status: Published application
- Kind: A1
- Application number: 15/030,416
- Filed: 2014-10-20
- Published: 2016-09-01
- Earliest claimed: 2013-10-21
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite Claude Bernard Lyon 1; Ens-Ecole Normale Superieure De Lyon; Centre National de la Recherche Scientifique (CNRS); Hospices Civils De Lyon
- Applicants: Inserm (Institut National De La Santé Et De La Recherche MéDicale; Université Claude Bernard - Lyon 1; Ens - Ecole Normale SupéRieure De Lyon; Centre National De La Recherche Scientifique (Cnrs); Hospices Civils De Lyon
- Inventors: Vincent Lotteau; Patrice Andre; Benoit De Chassey; Laurene Meyniel-Schicklin; Irene Pilar Castellanos
- Web page: https://patentgrep.com/patent/US20160250245A1

## CPC

- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 13/12: of the kidneys
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of polyomavirus infections. In particular, the present invention relates to a method for treating a polyomavirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of gemcitabine.

## Claims

### Claim 1

A method of treating a polyomavirus infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of gemcitabine or a gemcitabine derivative.

### Claim 2 (depends on 1)

The method of claim 1 wherein the polyomavirus is selected from the group consisting of JCV, BKV, KI virus, WU virus, Merkel cell polyomavirus (MCV), Trichodysplasia sinulosa-associated polyomavirus (TSV), HPyV6, HPyV7, and HPyV9.

### Claim 3 (depends on 1)

The method of claim 1 wherein the polyomavirus is BK virus.

### Claim 4 (depends on 1)

The method of claim 1 wherein the subject has or is suspected of having a latent polyomavirus infection.

### Claim 5 (depends on 1)

The method of claim 1 wherein the subject has been diagnosed with an active polyomavirus infection

### Claim 6 (depends on 1)

The method of claim 1 wherein the subject is at risk of developing a disease associated with a polyomavirus, and is selected from the group consisting of individuals diagnosed with an active polyomavirus infection, individuals who are immunocompromised and diagnosed with an active polyomavirus infection, and individuals who are immunocompromised and have or are suspected of having a latent polyomavirus infection.

### Claim 7 (depends on 6)

The method of claim 6 wherein the individuals who are immunocompromised are selected from the group consisting of AIDS patients; patients on chronic immunosuppressive treatment regimens, patients with cancer, patients with autoimmune conditions being treated with mycophenolate mofetil or a biologic, and elderly patients with weakened immune systems that have or are suspected of having a latent polyomavirus infection.

### Claim 8 (depends on 7)

The method of claim 7 wherein the patients on chronic immunosuppressive treatment regimens are organ transplant patients to whom an immunosuppressive agent is administered.

### Claim 9 (depends on 8)

The method of claim 8 wherein the organ transplant patients have at least one transplanted organ selected from the group consisting of kidney, bone marrow, liver, lung, stomach, bone, testis, heart, pancreas and intestine.

### Claim 10 (depends on 6)

The method of claim 6 wherein the gemcitabine or gemcitabine derivative is administered in concurrent or sequential combination with an immunosuppressive agent.

### Claim 11 (depends on 10)

The method of claim 10 wherein the immunosuppressive agent is selected from the group consisting of antibodies that specifically bind to CD20, CD25 or CD3; calcineurin inhibitors interferons steroids; interleukin-1 receptor antagonists; myophenolate mofetil; Prograph®; azathioprine; methotrexate; and TNF-α binding proteins.

### Claim 12

A method for the prophylactic treatment of a disease associated with polyomaviruses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of gemcitabine.

### Claim 13 (depends on 12)

The method of claim 12 wherein the disease associated with polyomaviruses is selected from the group consisting of progressive multifocal leukoencephalopathy (PML), neural tumors, colorectal cancer, prostate cancer, Merkel cell carcinoma, nephritis and/or nephropathy in patients who have undergone renal transplantation, hemorrhagic-cystitis in patients who have undergone a bone marrow or stem cell transplant, and non hemorrhagic cystitis in patients who have undergone a bone marrow or stem cell transplant.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the gemcitabine derivative is a compound of formula:
wherein R1 and R3 are hydrogen and R2 is a C18- or C20-saturated or monounsaturated acyl group, or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the gemcitabine derivative is gemcitabine-5-elaidate, or gemcitabine-5-elaidate ester which has the structure of formula:

### Claim 16 (depends on 1)

The method according to claim 1, wherein the gemcitabine derivative is selected from the group consisting of compounds having the general formula (I) to (VIII):
wherein R1 to R4 represent hydrogen or nitrogen protecting groups.

### Claim 17 (depends on 16)

The method of claim 16 wherein R1, R2 and R3 are independently selected from hydrogen and C1 to C30 saturated, monounsaturated or polyunsaturated acyl groups.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the gemcitabine derivative is selected from the group consisting of 2′-Deoxy-2̂2′-difiuoro-D-cytidme-5,0-bis(ethoxy-L-alaninyl)-phosphate; 2′-Deoxy-2̂2′-difluoro-D-cytidme-5′-0-bis(benzoxy-L-alaiiinyl)-phosphate; 2′-Deoxy-2,2′-difluoro-D-cytidme-5′-0-bis(cyclohexoxy-L-alaninyl)-phosphate; 2′-Deoxy-2̂2̂-difluoro-D-cytidme-5′-0-bis(2,2-dimethylpropoxy-L-alani phosphate; and 2′-Deoxy-2 2′-difluoro-D-cvtidme-5′-0-bis(iso-propoxy-L-alaninyl)-phosphate.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the gemcitabine derivative is a pegylated gemcitabine derivative.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the gemcitabine or gemcitabine derivative is administered to the subject in manner to reach an active concentration in the nanomolar range.

### Claim 21 (depends on 20)

The method of claim 20 wherein the gemcitabine or gemcitabine derivative is administered to the subject to reach a concentration of about 1; 1.05; 1.1; 1.15; 1.2; 1.25; 1.3; 1.35; 1.4; 1.45; 1.5; 1.55; 1.6; 1.65; 1.7; 1.75; 1.8; 1.85; 1.9; 1.95; 2; 2.05; 2.1; 2.15; 2.2; 2.25; 2.3; 2.35; 2.4; 2.45; 2.5; 2.55; 2.6; 2.65; 2.7; 2.75; 2.8; 2.85; 2.9; 2.95; 3; 3.05; 3.1; 3.15; 3.2; 3.25; 3.3; 3.35; 3.4; 3.45; 3.5; 3.55; 3.6; 3.65; 3.7; 3.75; 3.8; 3.85; 3.9; 3.95; 4; 4.05; 4.1; 4.1; 4.15; 4.2; 4.25; 4.3; 4.35; 4.4; 4.45; 4.5; 4.55; 4.6; 4.65; 4.7; 4.75; 4.8; 4.85; 4.9; 4.95; 5; 5.05; 5.1; 5.15; 5.2; 5.25; 5.3; 5.35; 5.4; 5.45; 5.5; 5.55; 5.6; 5.65; 5.7; 5.75; 5.8; 5.85; 5.9; 5.95; 6; 6.05; 6.1; 6.15; 6.2; 6.25; 6.3; 6.35; 6.4; 6.45; 6.5; 6.55; 6.6; 6.65; 6.7; 6.75; 6.8; 6.85; 6.9; 6.95; 7; 7.05; 7.1; 7.15; 7.2; 7.25; 7.3; 7.35; 7.4; 7.45; 7.5; 7.55; 7.6; 7.65; 7.7; 7.75; 7.8; 7.85; 7.9; 7.95; 8; 8.05; 8.1; 8.15; 8.2; 8.25; 8.3; 8.35; 8.4; 8.45; 8.5; 8.55; 8.6; 8.65; 8.7; 8.75; 8.8; 8.85; 8.9; 8.95; 9; 9.05; 9.1; 9.15; 9.2; 9.25; 9.3; 9.35; 9.4; 9.45; 9.5; 9.55; 9.6; 9.65; 9.7; 9.75; 9.8; 9.85; 9.9; 9.95; or 10 nM.

### Claim 22 (depends on 7)

The method of claim 7, wherein the patients with cancer are Hodgkin's disease patients or lymphoma patients.

### Claim 23 (depends on 7)

The method of claim 7, wherein the biologic is natalizumab, rituximab, or efalizumab,

### Claim 24 (depends on 11)

The method of claim 11, wherein the calcineurin inhibitor is selected from the group consisting of ciclosporin, pimecrolimus, tacrolimus, sirolimus and cyclosporine.

### Claim 25 (depends on 13)

The method of claim 13, wherein the neural tumor is a medulloblastoma, an oligodendroglioma, an astroglioma or a glioblastoma.

### Claim 26 (depends on 16)

The method of claim 16, wherein the nitrogen protecting group is an ester, an amide, an acetal or a ketal.

### Claim 27 (depends on 17)

The method of claim 17, wherein the C1 to C30 saturated monounsaturated or polyunsaturated acyl groups are
i) C8 to C26 saturated, monounsaturated or polyunsaturated acyl groups or
ii) C12 to C24 saturated, monounsaturated or polyunsaturated acyl groups.
